Jolanta Tanianis-Hughes

Author

Also Known As

Aarti Shah, Agnieska Szemiel, Aislynn Taggart, Alejandra Doce Carracedo, J. Tanianis-Hughes, Joanna Middleton, Jolanta Tanianis-Hughes, Joyce Mitchell, Krishanthi S Subramaniam, Krishanthi S. Subramaniam

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

University of Manchester University of Oxford Salford Royal Hospital Roslin Institute University of Edinburgh

About

Jolanta Tanianis-Hughes is an author at University of Manchester specializing in medicine, pharmacology, and glycobiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	315
2	Biochemistry	1	1	77
3	Cellular Physiology	1	1	77
4	Immunology	1	1	167
5	Microbiology	1	1	167

Jolanta Tanianis-Hughes

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Bax Exists in a Dynamic Equilibrium between the Cytosol and Mitochondria to Control Apoptotic Priming Barbara Schellenberg, Pengbo Wang, James A. Keeble, Molecular Cell	2013	231
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study Rishi K Gupta, Ewen M. Harrison, Antonia Ho, The Lancet Respiratory Medicine	2021	224
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK Chloë I. Bloom, Thomas M Drake, Annemarie B Docherty, The Lancet Respiratory Medicine	2021	192
Interferon γ Induces Translocation of Commensal Escherichia coli Across Gut Epithelial Cells via a Lipid Raft--Mediated Process Edwin C. Clark, Catherine J. Hoare, Jolanta Tanianis-Hughes, Gastroenterology DysbiosisMucosal ImmunologyMicrobial PathogensMedicinePathogenesis	2005	167
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study Thomas M Drake, Aya Riad, Cameron J Fairfield, The Lancet	2021	161
Region-Dependent Modulation of Intestinal Permeability by Drug Efflux Transporters: In Vitro Studies in mdr1a(−/−) Mouse Intestine R. Stephens, Jolanta Tanianis-Hughes, N. B. Higgs, Journal of Pharmacology and Experimental Therapeutics	2002	96
The impact of viral mutations on recognition by SARS-CoV-2 specific T cells Thushan I. de Silva, Guihai Liu, Benjamin B. Lindsey, iScience	2021	89
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer Fiona Foster, Thomas W. Owens, Jolanta Tanianis-Hughes, Breast Cancer Research	2009	82
Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Andrew Collett, Jolanta Tanianis-Hughes, G. Warhurst Biochemical Pharmacology Rapid InductionBiochemistryMedicineMembrane TransportHigh Permeability Compounds	2004	77
Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo Andrew Collett, Jolanta Tanianis-Hughes, David Hallifax, Pharmaceutical Research MedicinePhysiologyOral AbsorptionDrug PharmacokineticsPharmacotherapy	2004	71

Page 1